Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 96.40
+2.80 (2.99%)
Sep 30, 2025, 4:08 PM HKT
Innovent Biologics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | -94.63 | -1,028 | -2,179 | -2,729 | -998.42 | Upgrade |
Depreciation & Amortization | 332.16 | 310.22 | 276.79 | 202.17 | 85.63 | Upgrade |
Other Amortization | 87.61 | 74.89 | 42.64 | 2.58 | - | Upgrade |
Loss (Gain) From Sale of Assets | 22.99 | 0.95 | -0.06 | 0.71 | 1.2 | Upgrade |
Asset Writedown & Restructuring Costs | 632.57 | 115.36 | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | -179.03 | -30.81 | -5.1 | -125.02 | -30.98 | Upgrade |
Loss (Gain) on Equity Investments | 41.01 | - | - | - | - | Upgrade |
Stock-Based Compensation | 556.52 | 574.2 | 469.49 | 501.57 | 402.5 | Upgrade |
Other Operating Activities | -515.93 | -272.47 | -833.19 | 213.88 | 566.44 | Upgrade |
Change in Accounts Receivable | -178.52 | -430.62 | 393.14 | -493.03 | -225.34 | Upgrade |
Change in Inventory | 180.63 | 358.95 | -105.39 | -643.28 | -311.43 | Upgrade |
Change in Accounts Payable | -14.87 | 46.93 | 130.57 | 74.43 | 36.35 | Upgrade |
Change in Unearned Revenue | -31.19 | -138.63 | 205.04 | 105.43 | 55.12 | Upgrade |
Change in Other Net Operating Assets | 447.71 | 566.77 | -313.45 | 864.46 | 111.24 | Upgrade |
Operating Cash Flow | 1,287 | 147.81 | -1,919 | -2,025 | -307.69 | Upgrade |
Operating Cash Flow Growth | 770.73% | - | - | - | - | Upgrade |
Capital Expenditures | -965.67 | -1,119 | -896.9 | -1,066 | -489.02 | Upgrade |
Sale of Property, Plant & Equipment | 0.27 | 0.05 | 0.19 | 0.1 | 0.04 | Upgrade |
Sale (Purchase) of Intangibles | -676.42 | -262.35 | -468.6 | -781.88 | -32.63 | Upgrade |
Sale (Purchase) of Real Estate | - | 16.23 | - | - | - | Upgrade |
Investment in Securities | -981.19 | -204.43 | -384.74 | -254.58 | -4,490 | Upgrade |
Other Investing Activities | 1,458 | 571.22 | 314.87 | -596.15 | -173.02 | Upgrade |
Investing Cash Flow | -1,165 | -998.66 | -1,435 | -2,698 | -5,185 | Upgrade |
Long-Term Debt Issued | 515.57 | 1,336 | 1,080 | 1,463 | 372.18 | Upgrade |
Long-Term Debt Repaid | -1,246 | -948.85 | -392.74 | -278.72 | -33.79 | Upgrade |
Net Debt Issued (Repaid) | -730.44 | 386.7 | 687.43 | 1,184 | 338.39 | Upgrade |
Issuance of Common Stock | 84.31 | 2,255 | 2,131 | 3,951 | 4,662 | Upgrade |
Other Financing Activities | 39.5 | -54.56 | 73.59 | -131.52 | -88.63 | Upgrade |
Financing Cash Flow | -606.63 | 2,587 | 2,892 | 5,003 | 4,912 | Upgrade |
Foreign Exchange Rate Adjustments | 12.68 | -6.88 | 118.66 | -197.14 | -569.47 | Upgrade |
Net Cash Flow | -472.34 | 1,730 | -343.24 | 83.23 | -1,150 | Upgrade |
Free Cash Flow | 321.36 | -971.58 | -2,816 | -3,090 | -796.71 | Upgrade |
Free Cash Flow Margin | 3.41% | -15.65% | -61.80% | -72.38% | -20.73% | Upgrade |
Free Cash Flow Per Share | 0.20 | -0.62 | -1.89 | -2.12 | -0.59 | Upgrade |
Cash Interest Paid | 122.43 | 127.61 | 104.88 | 78.83 | 45.83 | Upgrade |
Cash Income Tax Paid | 0.16 | -114.42 | 66.1 | 26.44 | 139.71 | Upgrade |
Levered Free Cash Flow | -113.22 | -907.54 | -2,475 | -2,612 | -806.08 | Upgrade |
Unlevered Free Cash Flow | -70.94 | -845.9 | -2,411 | -2,573 | -763.36 | Upgrade |
Change in Working Capital | 403.76 | 403.39 | 309.91 | -91.98 | -334.06 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.